Skip to main content
Sfd Spolka Akcyjna logo

Sfd Spolka Akcyjna — Investor Relations & Filings

Ticker · SFD ISIN · PLSFD0000013 LEI · 259400VSMNUS19PYEL33 WAR Wholesale and retail trade
Open in API
Filings indexed 158 across all filing types
Latest filing 2026-02-13 Capital/Financing Update
Country PL Poland
Listing WAR SFD

About Sfd Spolka Akcyjna

http://www.sfdsa.pl

Sfd Spolka Akcyjna engages in the wholesale and retail of nutrients, dietary supplements, sports accessories, and dietetic foods. The company develops and markets an extensive portfolio of proprietary brands, including SFD NUTRITION, ALLNUTRITION, ALLDEYNN, Frulove, NUTLOVE, and FITKING DELICIOUS. These brands are designed to meet the needs of a diverse customer base, from professional athletes to individuals focused on physical fitness and a healthy lifestyle. Its product offerings range from protein supplements and nutricosmetics to healthy alternatives for sweets, pre-workout formulas, and balanced meals. The company distributes its products through online channels, stationary shops, and gyms.

Recent filings

Filing Released Lang Actions
Zawarcie umowy o dofinansowanie projektu w ramach programu FENG - Content (PL)
Capital/Financing Update Classification · 1% confidence The document is a regulatory announcement from SFD S.A. regarding the signing of a funding agreement with the National Centre for Research and Development (NCBR) for a specific R&D project. It details the project scope, budget, and expected impact on the company's competitive position. Since this is a specific corporate announcement regarding financing/capital project funding that does not fit into the other specific categories like M&A or share issues, it is best classified as a general regulatory filing.
2026-02-13 Polish
Zakończenie publikacji raportów miesięcznych na skutek zmiany Dobrych Praktyk Spółek Notowanych na NewConnect - Content (PL)
Report Publication Announcement Classification · 1% confidence The document text, written in Polish, discusses the cessation of publishing 'raportów miesięcznych' (monthly reports) due to changes in the 'Dobre Praktyki Spółek Notowanych na NewConnect 2024' (Good Practices for Companies Listed on NewConnect 2024). The core subject is the discontinuation of a specific type of periodic reporting (monthly reports) based on new corporate governance rules. This is an announcement regarding a change in the company's reporting obligations or schedule, rather than the report itself. Since there is no specific code for 'Cessation of Monthly Reporting', and it is a formal announcement concerning regulatory compliance/reporting structure, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a formal notice to the market about a change in disclosure practice. Given the very short length (844 chars) and the nature of the announcement, RNS is the most appropriate fallback.
2024-05-14 Polish
zal02_opinia_ekspercka.pdf
Environmental & Social Information Classification · 1% confidence The document is titled "OPINIA EKSPERCKA NA TEMAT POCHODZENIA, WCHŁANIANIA ŹRÓDEŁ I MOŻLIWOŚCI ZAKAŻENIA RTĘCIĄ ZE SPOŻYCIEM WYBRANYCH PRODUKTÓW SPOŻYWCZYCH, W TYM SUPLEMENTÓW DIETY" (Expert Opinion on the Origin, Absorption of Sources, and Possibility of Mercury Contamination from the Consumption of Selected Food Products, Including Dietary Supplements). It contains detailed scientific analysis regarding mercury toxicity, accumulation, regulatory limits (citing EFSA and EU Regulations like 2023/915), and concludes with an "OŚWIADCZENIE FIRMY NA WYNIKI OZNACZEŃ ZAWARTOŚCI RTĘCI UZYSKANE W RAMACH URZĘDOWEJ KONTROLI ŻYWNOŚCI W WYBRANEJ PARTII SUPLEMENTU DIETY" (Company Statement on the Results of Mercury Content Determinations Obtained During Official Food Control in a Selected Batch of Dietary Supplement). This structure—an expert opinion/analysis followed by a company statement regarding regulatory findings—is highly characteristic of a specialized report or information document, rather than a standard regulatory filing like 10-K or an earnings release. Given the focus on scientific assessment, regulatory context, and the nature of the content (an expert opinion/report), the closest fit among the provided codes is 'Audit Report / Information' (AR), as it covers detailed analysis and results of internal/regulatory checks, even though it's not a traditional financial audit. It is a detailed informational report.
2023-09-14 Polish
zal01_2023-09-13_-_opinia_-_Hg_w_suplemencie_SFD.pdf
Audit Report / Information Classification · 1% confidence The document is a detailed technical opinion or report analyzing the presence of mercury in a specific dietary supplement ('SFD Crea@ne 200 cap'). It cites specific EU regulations (Regulation (EU) 2023/915) and scientific opinions (EFSA) regarding contaminant levels (PTWI) and compares the exposure risk from the supplement to that from fish consumption. This structure—a detailed analysis of a specific substance's safety profile based on regulatory limits and scientific literature, often involving testing results—aligns best with a formal Audit Report or Information document, especially since it is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA). It functions as a specialized safety assessment or internal/regulatory review finding, fitting the description of 'Audit Report / Information' (AR). The length (under 5,000 characters) and content suggest a focused report rather than a general regulatory filing (RNS) or a presentation (IP). FY 2023
2023-09-14 Polish
Otrzymanie dwóch niezależnych opinii toksykologicznych - Content (PL)
Environmental & Social Information Classification · 1% confidence The document is a current report (raport bieżący) from SFD S.A. detailing the receipt of two independent toxicological opinions regarding heavy metal contamination in creatine products. It discusses the findings, compares the risk to everyday food consumption (like tuna), and confirms that the health risk is low. Crucially, the last sentence states: "Rzeczone opinie stanowią załączniki do niniejszego raportu bieżącego" (The said opinions constitute attachments to this current report). Since the document itself is an announcement about receiving expert opinions and attaching them, and it deals with a specific legal/regulatory matter (product safety/contamination), it fits best under Legal Proceedings Report (LTR) if it were a lawsuit update, or more generally as a Regulatory Filing (RNS) if it's a mandatory disclosure not covered elsewhere. Given the subject matter—a specific regulatory/safety issue requiring expert review and disclosure—and the fact that it is an announcement *about* attached evidence rather than the full legal filing itself, RNS is the most appropriate general regulatory fallback. However, since the core content is an update on a significant legal/regulatory matter (product safety investigation/findings), LTR (Legal Proceedings Report) is a strong candidate, but RNS is safer for general mandatory disclosures that aren't strictly lawsuits. Given the context of product safety issues requiring expert review and disclosure, and the short length (1850 chars) suggesting it's an announcement rather than the full legal document, RNS (Regulatory Filings) is the most suitable general category for mandatory disclosures that don't fit the specific financial/governance codes.
2023-09-14 Polish
Otrzymanie informacji o wystąpieniu wady jakościowej w jednej kategorii produktowej SFD SA - Content (PL)
Legal Proceedings Report Classification · 1% confidence The document text is a formal communication from the Management Board (Zarząd) of SFD SA detailing a quality issue (heavy metal contamination in creatine batches) traced back to an external supplier. It outlines immediate corrective actions, including voluntary withdrawal of products, enhanced supplier auditing, and pre-emptive sales suspension. This type of disclosure, addressing a significant operational or legal risk that impacts product safety and business continuity, strongly suggests a regulatory filing or a specific announcement regarding legal/operational risks. Given the content focuses on a product recall/safety issue and subsequent operational changes, it aligns best with reporting on significant legal/regulatory matters or a general regulatory announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management discussion (MDA), and it details a significant operational/legal event, it fits best under the general 'Regulatory Filings' (RNS) category as a significant, non-standard disclosure, or potentially 'Legal Proceedings Report' (LTR) if the contamination issue leads to formal legal action, but RNS is the safer general regulatory fallback for such specific operational incidents not covered elsewhere. Given the immediate operational response and disclosure of a product safety failure, RNS is the most appropriate general regulatory category.
2023-09-08 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.